^
    1d
    Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov)
    P3, N=130, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Dec 2029 --> Nov 2027 | Trial primary completion date: Mar 2028 --> Dec 2026
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    paclitaxel • pegylated liposomal doxorubicin
    1d
    A Study of Propranolol to Treat Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Aug 2029 --> Jun 2027 | Trial primary completion date: Aug 2028 --> Jun 2027
    Trial completion date • Trial primary completion date
    1d
    Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01） (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Apr 2023 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib)
    1d
    Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase classification: P2 --> P=N/A | N=28 --> 50 | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity (clinicaltrials.gov)
    P=N/A, N=58, Recruiting, National Cancer Institute, Egypt
    New trial
    1d
    MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2025 --> Jan 2026
    Trial completion date • IO biomarker
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • lapatinib • Zykadia (ceritinib) • Tasigna (nilotinib) • Lytgobi (futibatinib) • Tabrecta (capmatinib) • Daurismo (glasdegib)
    1d
    Intravital Microscopy in Human Solid Tumors (clinicaltrials.gov)
    P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    1d
    Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors. (PubMed, Cell Death Dis)
    Our new unique mouse model will allow further studies of the effects of Trp53 nonsense mutation in a multi-organ system and serve as a model for the Li-Fraumeni syndrome (LFS). It will also be valuable for preclinical evaluation of novel therapeutic strategies for targeting TP53 nonsense mutations in cancer.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    1d
    Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors. (PubMed, J Immunother Cancer)
    These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.
    Journal
    |
    IL6 (Interleukin 6) • STING (stimulator of interferon response cGAMP interactor 1)
    1d
    Integrated Strategies of Network Pharmacology, Transcriptomics, and Computational and Experimental Validation Reveal the Anti-Osteosarcoma Effects of Juglone via the ROS/PI3K/AKT Pathway. (PubMed, Eur J Pharmacol)
    This study first demonstrates juglone's anti-OS efficacy via the ROS/PI3K/AKT pathway. In vivo studies confirm potent tumor suppression with short-term safety, supporting its clinical promise for OS treatment.
    Journal
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)